Key Highlights
- Kenvue's $0.21 quarterly Dividend trades ex-date September 21, 2026, payable October 2, yielding approximately 4.70%.
- Second-quarter net sales were approximately $4.0 billion, up 3.0% year over year, with Organic Sales up 1.6% after a 1.4% favorable foreign-exchange effect.
- Six-month net sales were $7.864 billion and Net Income was $930 million, up 25.3% from $742 million in the comparable prior-year period.
- Kenvue's pending combination with Kimberly-Clark remains subject to outstanding regulatory and closing conditions, with shareholders having approved the transaction in January 2026 and the U.S. HSR Waiting Period expiring in February.
Kenvue's (NYSE:KVUE) $0.21 quarterly dividend, declared September 10, 2026, yields approximately 4.70% and was announced alongside a period of six-month net income growth amid the company's pending combination with Kimberly-Clark. This is a new declaration with its own September 21 Record Date and October 2 payment date, distinct from an earlier $0.21 dividend the company had paid on August 26 to shareholders of record August 12.
Dividend Program and Shareholder Returns
Kenvue declared a $0.21 per share quarterly dividend on September 10, 2026, payable October 2 to shareholders of record September 21. The $0.21 quarterly rate equals $0.84 annualized if maintained. Six-month cash dividends paid were approximately $796 million. The company's Form 10-Q states that future dividend declarations remain at the discretion of the board and should be considered in the context of the pending Kimberly-Clark transaction and restrictions the Merger agreement places on certain capital-allocation actions.
About the Company
Kenvue is a consumer-health company separated from Johnson & Johnson in 2023, with brands including Tylenol, Listerine, Neutrogena, BAND-AID, Nicorette, Zyrtec and Aveeno, organized into Self Care, Skin Health and Beauty, and Essential Health segments.
Financial Performance Behind the Payout
Kenvue reported second-quarter net sales of approximately $4.0 billion, up $116 million, or 3.0%, from the prior-year quarter, with organic sales up 1.6% after a 1.4% favorable foreign-exchange effect. Gross Profit Margin declined 70 basis points to 58.2%, reflecting input-cost inflation, tariffs and foreign-exchange effects, partly offset by supply-chain optimization. Six-month net sales were $7.864 billion, gross profit was $4.603 billion, and net income was $930 million, up 25.3% from $742 million. At June 28, 2026, Kenvue had $1.110 billion of cash and $7.074 billion of long-term debt.
A Merger-Constrained Capital-Allocation Framework
Kenvue's pending combination with Kimberly-Clark, under which K-C would acquire Kenvue through approximately 0.14625 K-C shares plus $3.50 cash per Kenvue share, remains subject to outstanding regulatory and closing conditions as of the latest 10-Q, even though shareholders approved the transaction in January 2026 and the U.S. HSR waiting period expired in February. The merger agreement's restrictions on certain capital-allocation actions are a Factor the company itself identifies as relevant to evaluating future dividend declarations, meaning the $0.21 quarterly rate should be considered within that constrained framework rather than as an indicator of an independent, ongoing dividend-growth trajectory. Segment performance diverged this quarter, with Skin Health and Beauty generating the strongest organic growth while Self Care faced Volume pressure in some categories, according to the company's own characterization.
Outlook
Kenvue's dividend continues within the capital-allocation framework constrained by the pending Kimberly-Clark merger agreement. Remaining regulatory and closing conditions for the transaction, organic sales trends across the Self Care, Skin Health and Beauty, and Essential Health segments, and any developments regarding capital-allocation restrictions tied to the pending combination are the relevant considerations.

_09_30_2026_02_08_20_566201.jpg)




Please wait processing your request...